ArticleQuantitative imaging in medicine and surgery2026
Percutaneous iodixanol localization of pulmonary ground-glass nodules for synchronous microwave ablation and biopsy: a multicenter, retrospective, matched analysis.
Article in Quantitative imaging in medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Synchronous microwave ablation (MWA) and biopsy are suitable for patients with high-risk pulmonary ground-glass nodules (GGNs) who are unfit for resection. The ablation accuracy is affected by hemorrhage and nodule displacement. We thus aimed to verify whether iodixanol localization could enhance the accuracy of the synchronous MWA and biopsy of GGNs. Methods: A total of 211 continuous patients who underwent synchronous MWA and biopsy were enrolled in a multicenter retrospective study from January 1, 2021, to December 31, 2022. Patients undergoing synchronous MWA and biopsy under conventional computed tomography (CT) guidance were placed in the conventional CT guidance for synchronous MWA and biopsy (cSMB) group and those with iodixanol localization were placed in the iodixanol localization for synchronous MWA and biopsy (iSMB) group. The primary outcomes included primary technique efficacy rate (defined as complete ablation based on a CT scan at 3 months), positive biopsy rate, and complications. In addition to an analysis of the overall cohort, data were compared in propensity score matching for GGN characteristics to minimize the impact of confounding factors. Results: Compared to the cSMB group (n=108), the iSMB group (n=103) had a higher primary technique efficacy rate (100.0% Conclusions: Iodixanol localization during synchronous MWA and biopsy of GGNs is efficient and safe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.